iRadimed (NASDAQ:IRMD) CEO Sells $261,144.06 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 3,089 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $84.54, for a total value of $261,144.06. Following the completion of the sale, the chief executive officer owned 2,184,411 shares in the company, valued at $184,670,105.94. This represents a 0.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Up 0.6%

iRadimed stock traded up $0.52 during midday trading on Wednesday, reaching $85.27. The stock had a trading volume of 71,131 shares, compared to its average volume of 86,931. iRadimed Corporation has a 12 month low of $50.88 and a 12 month high of $107.90. The firm’s 50-day moving average price is $94.77 and its 200 day moving average price is $94.62. The firm has a market capitalization of $1.09 billion, a PE ratio of 46.60 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities research analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is currently 43.72%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 6th. Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, iRadimed currently has a consensus rating of “Buy” and an average target price of $120.00.

Institutional Investors Weigh In On iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC increased its position in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after purchasing an additional 33,072 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of iRadimed in the third quarter worth approximately $422,000. Tudor Investment Corp ET AL bought a new position in shares of iRadimed in the third quarter worth approximately $666,000. RFG Advisory LLC bought a new position in shares of iRadimed in the fourth quarter worth approximately $1,594,000. Finally, USA Financial Formulas bought a new position in shares of iRadimed in the fourth quarter worth approximately $82,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.